[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oral-pre-exposure-prophylaxis-prep\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oral-pre-exposure-prophylaxis-prep":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100642577","betterinfo-on-womens-prep-choices-and-outcomes-in-malawi-100642577",false,"NCT07579754","BetterInfo on Women's PrEP Choices and Outcomes in Malawi","BetterInfo Tracing Approach to Evaluate HIV PrEP Choices and Use Over Time Among Women in Blantyre, Malawi","Inclusion Criteria:\n\nThe population for this research includes women aged 18 years or older at risk of HIV who initiated injectable or oral PrEP at one of the 20 Blantyre sites supported through PathToScale. PathToScale supports various types of facilities including public health clinics, drop-in centers for prioritized populations (DICs), and private hospitals\u002Fclinics.\n\nThose eligible for sampling are as follows:\n\n* Adult women ≥18 years; and\n* Initiated PrEP (injectable or oral) at the implementing facilities and lost to follow up within prior 2 years prior to sampling; and\n* Lost-to-follow-up (missed their PrEP visit by ≥3 months and for whom outcomes are unknown); and\n* Has a registered phone number for contact\n\nThose eligible for tracing are as follows:\n\n* Women sampled per eligibility criteria above; and\n* Women who have indicated permission for in-person follow-up\n\nHealth Care Providers, Implementing Partners, Ministry of Health (MOH) Stakeholers\n\n* providers and implementing partners from PathtoScale, and Ministry of Health stakeholders will be consented to participate in in-depth-interviews\n\nExclusion Criteria:\n\nThose excluded from sampling or tracing include:\n\n* Women who have an EMR record of a documented case of discontinuation of PrEP in consultation with a provider; or\n* Women who are known to have died; or\n* Women who have EMR documented transfers out of PathToScale supported facilities; or\n* Women refusing follow-up via phone on their ScanForm; or\n* Women refusing follow-up in person (during phone tracing); or\n* Women who do not speak Chichewa or English; or\n* Men (excluded from client interviews only)",true,"FEMALE","18 Years","110 Years",{"count":21,"type":22},384,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this study is to understand PrEP user choices, preferences and implementation impact of the roll-out of long-acting injectable PrEP alongside oral PrEP among women in Blantyre, Malawi.",[28,29],"Long-acting Injectable Cabotegravir for PrEP","Oral Pre-Exposure Prophylaxis (PrEP)",[31,32,33,34,35,36],"Implementation Science","Long-acting injectable cabotegravir for PrEP","Oral pre-exposure prophylaxis (PrEP)","HIV","pre-exposure prophylaxis (PrEP)","Lost-to-follow up (LTFU)","NOT_YET_RECRUITING","2026-06-12",{"date":40,"type":41},"2026-06-15","ACTUAL",{"date":43,"type":22},"2026-06",{"date":45,"type":22},"2029-04",{"name":47,"class":48},"Johns Hopkins Bloomberg School of Public Health","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":16,"sex":57,"minAge":58,"maxAge":19,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":49},"100609989","pathtoscale-the-persist-trial-100609989","NCT07221747","PathToScale: The PERSIST Trial","ACCELERATING THE PATH TO SCALE FOR INJECTABLE HIV PRE-EXPOSURE PROPHYLAXIS (PrEP) in MALAWI: THE PERSIST TRIAL","Inclusion Criteria:\n\n•Inclusion criteria for long-acting injectable cabotegravir for pre-exposure prophylaxis will be applied per Ministry of Health guidelines. Per Ministry of Health guidelines, the following populations will be prioritized for long-acting injectable cabotegravir for pre-exposure prophylaxis distribution, following individual risk assessment:\n\nIndividuals who are 15+ years old AND either\n\n1. Female sex workers (FSW) OR\n2. Men who have sex with men (MSM) OR\n3. Transgender individuals (TG) OR\n4. Women and adolescent girls and young women (AGYW) presenting at STI services and\u002For family planning and\u002For HIV testing services OR\n5. Breastfeeding women (BFW) OR\n6. Male partners of female sex workers and\u002For Men at high risk for HIV and\u002For men presenting with a syndromic or lab-confirmed sexually transmitted infections. All individuals initiated on long-acting injectable cabotegravir for pre-exposure prophylaxis 15 years or above will be included in the passively enrolled sample.\n\nExclusion Criteria:\n\n* Per Ministry of Health guidelines, exclusion criteria for long-acting injectable cabotegravir for pre-exposure prophylaxis includes:\n\nThose living with HIV-1 or evidence of possible acute HIV infection OR Those with a prior Hepatitis B diagnosis OR Those with a known history of severe side effects to Cabotegravir Long Acting OR Those unwilling or unable to return for 3-monthly HIV testing or 2-monthly counseling and safety monitoring visits OR Clients currently on multi-drug resistance tuberculosis (MDR-TB) medications OR Clients currently taking post-exposure prophylaxis.","ALL","15 Years",{"count":60,"type":22},9900,[25],"The purpose of this study is to identify the effectiveness of a bundle of strategies to support continuation of clients on pre-exposure prophylaxis, including long-acting injectable cabotegravir and oral pre-exposure prophylaxis to high priority groups.",[64,28],"Oral Pre-exposure Prophylaxis (PrEP)","RECRUITING","2026-03-02",{"date":68,"type":41},"2026-03-04",{"date":70,"type":41},"2026-02-16",{"date":72,"type":22},"2026-11",{"name":74,"class":48},"Georgetown University"]